PAVmed Inc.: Form 10-Q for the period ended Jun 30, 2024
Filed with the SEC on Aug 12, 2024 and accepted by EDGAR at Aug 12, 2024, 16:08 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-04-01 to 2024-06-30 | $979.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2024-01-01 to 2024-06-30 | $2.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-04-01 to 2024-06-30 | $1.7m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2024-01-01 to 2024-06-30 | $3.4m | us-gaap:CostOfRevenue |
| Research and development | 3 months2024-04-01 to 2024-06-30 | $1.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2024-01-01 to 2024-06-30 | $3.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-04-01 to 2024-06-30 | −$13.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-01-01 to 2024-06-30 | −$27.7m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2024-04-01 to 2024-06-30 | −$10.8m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-01-01 to 2024-06-30 | −$26.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-04-01 to 2024-06-30 | −$1.19 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-01-01 to 2024-06-30 | −$3.78 | us-gaap:EarningsPerShareDiluted |
| Diluted shares (weighted) | 3 months2024-04-01 to 2024-06-30 | 9,152,819 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-01-01 to 2024-06-30 | 8,923,862 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-01-01 to 2024-06-30 | −$24.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2024-01-01 to 2024-06-30 | $45.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-06-30 | $25.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-06-30 | $30.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-06-30 | $39.4m | us-gaap:Assets |
| Current liabilities | At period end2024-06-30 | $53.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-06-30 | $58.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-06-30 | −$73.9m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2024-06-30 | 10,010,844 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001493152-24-031268. Last ingested by Listed: Nov 3, 2026, 20:30 ET. Listed shows no prices and gives no investment advice.